Orchid Pharma Limited (NSE:ORCHPHARMA)
India · Delayed Price · Currency is INR 777.10
-15.40 (-1.94%)
Jun 1, 2026, 3:30 PM IST
Orchid Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 8,113 | 9,219 | 8,194 | 6,659 | 5,596 |
Other Revenue | 351.73 | - | - | - | - |
| 8,465 | 9,219 | 8,194 | 6,659 | 5,596 | |
Revenue Growth (YoY) | -8.18% | 12.52% | 23.05% | 19.00% | 24.33% |
Cost of Revenue | 5,259 | 5,672 | 5,032 | 4,013 | 3,271 |
Gross Profit | 3,206 | 3,548 | 3,162 | 2,646 | 2,325 |
Selling, General & Admin | 914.69 | 882.37 | 729.83 | 663.66 | 648.58 |
Other Operating Expenses | 1,529 | 1,490 | 1,323 | 1,145 | 1,145 |
Operating Expenses | 2,798 | 2,718 | 2,386 | 2,357 | 2,664 |
Operating Income | 408.49 | 829.5 | 776.25 | 289.93 | -338.9 |
Interest Expense | -132.59 | -145.4 | -163.55 | -322.26 | -320.12 |
Interest & Investment Income | - | 172.77 | 163.48 | 6.18 | 4.19 |
Earnings From Equity Investments | -6.61 | 38.99 | -28.98 | -21.54 | -35.23 |
Currency Exchange Gain (Loss) | - | 64.29 | 67.35 | 52.01 | 75.82 |
Other Non Operating Income (Expenses) | - | 37.68 | 77.8 | 126.6 | 4.9 |
EBT Excluding Unusual Items | 269.29 | 997.83 | 892.36 | 130.93 | -609.34 |
Gain (Loss) on Sale of Investments | - | - | - | 0.15 | 5.12 |
Gain (Loss) on Sale of Assets | - | -3.2 | -1.88 | 7.75 | 0 |
Other Unusual Items | -65.74 | - | - | 392.1 | - |
Pretax Income | 203.55 | 994.63 | 890.47 | 530.93 | -604.21 |
Income Tax Expense | -1.92 | -1.94 | -31.19 | - | - |
Earnings From Continuing Operations | 205.47 | 996.57 | 921.67 | 530.93 | -604.21 |
Earnings From Discontinued Operations | - | - | - | -67.75 | 584.7 |
Net Income | 205.47 | 996.57 | 921.67 | 463.18 | -19.51 |
Net Income to Common | 205.47 | 996.57 | 921.67 | 463.18 | -19.51 |
Net Income Growth | -79.38% | 8.13% | 98.98% | - | - |
Shares Outstanding (Basic) | 51 | 51 | 48 | 41 | 41 |
Shares Outstanding (Diluted) | 51 | 51 | 48 | 41 | 41 |
Shares Change (YoY) | 0.03% | 4.87% | 18.49% | - | - |
EPS (Basic) | 4.05 | 19.65 | 19.06 | 11.35 | -0.48 |
EPS (Diluted) | 4.05 | 19.65 | 19.06 | 11.35 | -0.48 |
EPS Growth | -79.39% | 3.11% | 67.93% | - | - |
Free Cash Flow | -2,824 | -1,309 | 611.77 | -665.75 | 780.71 |
Free Cash Flow Per Share | -55.66 | -25.81 | 12.65 | -16.31 | 19.13 |
Gross Margin | 37.88% | 38.48% | 38.59% | 39.74% | 41.55% |
Operating Margin | 4.83% | 9.00% | 9.47% | 4.35% | -6.06% |
Profit Margin | 2.43% | 10.81% | 11.25% | 6.96% | -0.35% |
Free Cash Flow Margin | -33.36% | -14.20% | 7.47% | -10.00% | 13.95% |
EBITDA | 763.02 | 1,170 | 1,094 | 837.72 | 531.03 |
EBITDA Margin | 9.01% | 12.69% | 13.35% | 12.58% | 9.49% |
D&A For EBITDA | 354.53 | 340.42 | 317.72 | 547.79 | 869.93 |
EBIT | 408.49 | 829.5 | 776.25 | 289.93 | -338.9 |
EBIT Margin | 4.83% | 9.00% | 9.47% | 4.35% | -6.06% |
Revenue as Reported | 8,465 | 9,494 | 8,502 | 6,853 | 5,686 |